急性心力衰竭患者应用沙库巴曲缬沙坦疗效分析

The Efficiency of Sacubitril/Valsartan in Patients With Acute Heart Failure

目的评估急性心力衰竭(AHF)患者院内起始应用沙库巴曲缬沙坦的临床疗效。方法收集49例于2018年8月—2020年1月入院的急性心力衰竭患者。血流动力学稳定后,给予沙库巴曲缬沙坦治疗,分析3个月后左心室结构、射血分数及NT-proBNP的变化,观察不良反应。结果治疗后,患者左室舒张末内径(LVEDD)较前明显缩小,左室射血分数(LVEF)明显升高(P<0.05);血清NT-proBNP水平较治疗前明显降低(P<0.05),血清肌酐、钾离子水平较前无明显改变(P>0.05),治疗及随访期间无明显不良反应发生。结论急性心力衰竭患者院内起始应用沙库巴曲缬沙坦有效改善患者心功能,逆转心脏重构,无明显不良反应。

Objective To evaluate the Clinical effect of the in-hospital initiation of sacubitril/valsartan in patients who are hospitalized for acute heart failure(AHF).Methods Forty-nine patients of acute heart failure were enrolled from February 2018 to January 2020.After hemodynamic stabilizaton patients were received sacubitril/valsartan.The changes of left ventricular structure,the left ventricular ejection fraction(LVEF)and NT-proBNP were analyzed after three months treatment.The incidence of adverse reactions were observed.Results After therapy,the left ventricular end-diastolic diameter(LVEDD)significantly reduced,the left ventricular ejection fraction(LVEF)significantly increased(P<0.05).The level of serum NT-proBNP significantly decreased(P<0.05).No significant change was found in the levels of serum creatinine and potassium than before therapy(P>0.05).There were no obvious adverse reactions during treatment and follow-up.Conclusion The in-hospital initiation of sacubitril/valsartan can effectively improve the cardiac function,reverse the cardiac remodeling and without obvious adverse reactions in the therapy of acute heart failure.